Contact | Print version | PDF version | Send article | RSS feed

Galapagos extends drug discovery collaboration with Amgen into 2010

22 Dec 2008 - Galapagos NV announced that its service division BioFocus DPI has extended its longstanding drug discovery collaboration with Amgen through 2009 and 2010. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen's discovery programs. Under the terms of the extended agreement, Galapagos will receive €2.0 M ($2.55 M) in research fees per year for two years. Additionally, Galapagos is eligible to receive compensation in the form of access fees and success-based milestones.
 
The collaboration, which was initiated in 2003 and extended in 2006, involves the identification of new molecules against drug targets from various protein classes, including ion channels, GPCRs and kinases.